Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
  • 2-acetyloxy-4-(trifluoromethyl)benzoic acid
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.005.726 Edit this at Wikidata
Chemical and physical data
Molar mass248.157 g·mol−1
3D model (JSmol)
  • CC(=O)Oc1cc(ccc1C(=O)O)C(F)(F)F
  • InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16) ☒N
 ☒NcheckY (what is this?)  (verify)

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a derivative of acetylsalicylic acid (ASA) in which a hydrogen atom on the benzene ring has been replaced by a trifluromethyl group. Trade names include Disgren, Grendis, Aflen and Triflux.[1]

Triflusal has multiple mechanisms of action that contribute to the effect of the drug. It is a COX-1 inhibitor. It also inhibits the activation of nuclear factor k-B, which in turn regulates the expression of the mRNA of the vascular cell adhesion molecule-1 needed for platelet aggregation. Additionally, Triflusal preserves vascular prostacyclin which yields an anti-platelet effect. Triflusal also blocks phosphodiesterase, increasing cAMP concentration as well as can increase nitric oxide synthesis in neutrophils.

Mechanism of action

Triflusal is a selective platelet antiaggregant through;


Triflusal is indicated for;

Prevention of stroke

In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid plus dipyridamole, or clopidogrel alone for secondary prevention of atherothrombotic stroke. This recommendation was based on the double-blind, randomised TACIP and TAPIRSS trials, which found triflusal to be equally as effective as Aspirin in preventing post-stroke vascular events, while having a more favourable safety profile.[3][4][5]


It is absorbed in the small intestine and its bio-availability ranges from 83% to 100%.[6][7] The active metabolite of Triflusal is 2-hydroxy-4-trifluoromethyl-benzoic acid, which is when Triflusal gets metabolized by an esterase.


  1. ^ Murdoch D, Plosker GL (2006). "Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation". Drugs. 66 (5): 671–92. doi:10.2165/00003495-200666050-00009. PMID 16620146.
  2. ^ a b c d e PubChem. "Triflusal". Retrieved 2021-11-27.
  3. ^ Matías-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jiménez MD, Lago A, Melo T (April 2003). "Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial". Stroke. 34 (4): 840–8. doi:10.1161/01.STR.0000063141.24491.50. PMID 12649515. S2CID 1387069.
  4. ^ Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, et al. (April 2004). "Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study". Neurology. 62 (7): 1073–80. doi:10.1212/01.wnl.0000113757.34662.aa. PMID 15079004. S2CID 9065395.
  5. ^ European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. (2008). "Guidelines for management of ischaemic stroke and transient ischaemic attack 2008". Cerebrovascular Diseases. 25 (5): 457–507. doi:10.1159/000131083.
  6. ^ Ramis J, Mis R, Conte L, Forn J (1990). "Rat and human plasma protein binding of the main metabolite of triflusal". Eur J Pharmacol. 183: 1867–1868.
  7. ^ Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jané F (1991). "Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose". European Journal of Drug Metabolism and Pharmacokinetics. 16 (4): 269–73. doi:10.1007/BF03189971. PMID 1823870. S2CID 6287466.